THE 5-SECOND TRICK FOR PHARMA BLOGS

As things stand, the outlook for Alzheimer’s therapy is a bit more auspicious. Particularly, There's been a surge of pleasure – and an ensuing backwash of scepticism – pursuing the publication of full final results from Clarity Advert, a Stage III confirmatory trial with Eisai and Biogen’s anti-amyloid mAb, lecanemab, in early Alzheimer’s